^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rosmantuzumab (OMP-131R10)

    i
    Other names: OMP-131R10, OMP 131R10
    Associations

    News

    Trials
    Company:
    Mereo Biopharma
    Drug class:
    Protein kinase modulator, RSPO3 inhibitor
    Associations

    News

    Trials
    over1year
    RSPO3 regulates the radioresistance of Non-Small cell lung cancer cells via NLRP3 Inflammasome-Mediated pyroptosis. (PubMed, Radiother Oncol)
    The findings demonstrated that RSPO3 plays a crucial role in regulating NSCLC radioresistance via NLRP3 mediated pyroptosis. Targeting the RSPO3-NLRP3 inflammasome axis may offer a potential therapeutic strategy to enhance the efficacy of radiotherapy for NSCLC patients.
    Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3) • RSPO3 (R-Spondin 3) • RSPO1 (R-Spondin 1)
    |
    RSPO3 overexpression
    |
    rosmantuzumab (OMP-131R10)
    over5years
    Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. (PubMed, Cancer Cell)
    RSPO receptor, LGR4, is epigenetically upregulated and works through cooperation with HOXA9, a poor prognostic predictor. Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia.
    Journal
    |
    RSPO2 (R-Spondin 2)
    |
    rosmantuzumab (OMP-131R10)